Zobrazeno 1 - 10
of 39
pro vyhledávání: '"D, Piscopio A"'
Autor:
Nisha Holay, Alexander Somma, Mark Duchow, Milad Soleimani, Anna Capasso, Srividya Kottapalli, Joshua Rios, Uma Giri, Jennifer Diamond, Anna Schreiber, Anthony D. Piscopio, Carla Van Den Berg, S. Gail Eckhardt, Todd A. Triplett
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Histone deacetylase inhibitors (HDACi) are currently being explored for the treatment of both solid and hematological malignancies. Although originally thought to exert cytotoxic responses through tumor-intrinsic mechanisms by increasing expression o
Externí odkaz:
https://doaj.org/article/fb11b1e8367b473a9f32db554b699b48
Autor:
Anthony D. Piscopio, Xuedong Liu, S. Gail Eckhardt, William P. Schiemann, Michael K. Wendt, James D. Winkler, John A. DeMattei, Sarah J. Hartman, Brian Gittleman, John J. Tentler, Timothy P. Newton, Betelehem W. Yacob, Jessica Pafford, Stacey M. Bagby, Andrew J. Phillips, Gan Zhang, Christopher G. Nasveschuk, Dana Ungermannova, Todd M. Pitts, Jennifer R. Diamond
Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b66cc0ba3e4bb3154d809f1ce9e18868
https://doi.org/10.1158/1535-7163.22522086
https://doi.org/10.1158/1535-7163.22522086
Autor:
Anthony D. Piscopio, Xuedong Liu, S. Gail Eckhardt, William P. Schiemann, Michael K. Wendt, James D. Winkler, John A. DeMattei, Sarah J. Hartman, Brian Gittleman, John J. Tentler, Timothy P. Newton, Betelehem W. Yacob, Jessica Pafford, Stacey M. Bagby, Andrew J. Phillips, Gan Zhang, Christopher G. Nasveschuk, Dana Ungermannova, Todd M. Pitts, Jennifer R. Diamond
Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. Although HDAC inhibitors are active in T-cell lymphomas, poor isoform selectivity, narrow therapeutic indices, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca10d3d7a768f89abeba39b0600ff66
https://doi.org/10.1158/1535-7163.c.6543273
https://doi.org/10.1158/1535-7163.c.6543273
Autor:
Anthony D. Piscopio, Xuedong Liu, S. Gail Eckhardt, William P. Schiemann, Michael K. Wendt, James D. Winkler, John A. DeMattei, Sarah J. Hartman, Brian Gittleman, John J. Tentler, Timothy P. Newton, Betelehem W. Yacob, Jessica Pafford, Stacey M. Bagby, Andrew J. Phillips, Gan Zhang, Christopher G. Nasveschuk, Dana Ungermannova, Todd M. Pitts, Jennifer R. Diamond
Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21396584792a719c719476ad7fe8d703
https://doi.org/10.1158/1535-7163.22522083
https://doi.org/10.1158/1535-7163.22522083
Autor:
Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, John J. Tentler, Brian Gittleman, Sarah J. Hartman, John A. DeMattei, James D. Winkler, Michael K. Wendt, William P. Schiemann, S. Gail Eckhardt, Xuedong Liu, Anthony D. Piscopio
Publikováno v:
Mol Cancer Ther
Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. Although HDAC inhibitors are active in T-cell lymphomas, poor isoform selectivity, narrow therapeutic indices, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7f204038b194d4d2b23b9b7512f1bf
https://doi.org/10.1158/1535-7163.mct-21-0455
https://doi.org/10.1158/1535-7163.mct-21-0455
Autor:
Robert W. Robey, Christina M. Fitzsimmons, Wilfried M. Guiblet, William J.E. Frye, José M. González Dalmasy, Li Wang, Drake A. Russell, Lyn M. Huff, Andrew J. Perciaccante, Fatima Ali-Rahmani, Crystal C. Lipsey, Heidi M. Wade, Allison V. Mitchell, Siddhardha S. Maligireddy, David Terrero, Donna Butcher, Elijah F. Edmondson, Lisa M. Jenkins, Tatiana Nikitina, Victor B. Zhurkin, Amit K. Tiwari, Anthony D. Piscopio, Rheem A. Totah, Susan E. Bates, H. Efsun Arda, Michael M. Gottesman, Pedro J. Batista
Histone deacetylase inhibitors (HDACis) are part of a growing class of epigenetic therapies used for the treatment of cancer. While elevated levels of the efflux pump P-gp are associated within vitroresistance to romidepsin, this mechanism does not t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0eab6c73a6fa5f6f5baa893e9093b0da
https://doi.org/10.1101/2022.10.07.511310
https://doi.org/10.1101/2022.10.07.511310
Autor:
Brittany C. Waschke, Rachel A. Woolaver, Jing Wang, Anthony D. Piscopio, Xuedong Liu, Gan Zhang, Xiaoguang Wang, Zhangguo Chen
Publikováno v:
Cancer Immunology Research. 7:1318-1331
PD1 blockade is effective in a subset of patients with B-cell lymphoma (e.g., classical-Hodgkin lymphomas); however, most patients do not respond to anti-PD1 therapy. To study PD1 resistance, we used an isoform-selective histone deacetylase inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07246219ed47d3bb94a2fd68183e0344
https://doi.org/10.1158/2326-6066.cir-18-0875
https://doi.org/10.1158/2326-6066.cir-18-0875
Autor:
S. Lindsey Davis, Gilad Gordon, S. Gail Eckhardt, Jose M. Pacheco, Anthony D. Piscopio, James D. Winkler, Amy M. Heim, Christopher H. Lieu, Bradley R. Corr, Jennifer R. Diamond, Todd A. Triplett, Sunnie S. Kim, Jodi A. Kagihara, John A. DeMattei, Antonio Jimeno
Publikováno v:
Journal of Clinical Oncology. 39:3075-3075
3075 Background: OKI-179 is a novel, oral pro-drug analog of largazole, a compound in the romidepsin-depsipeptide class of natural products. OKI-006, the active metabolite of OKI-179, inhibits HDAC 1,2,3 (IC50 = 1.2, 2.4, 2.0 nM, respectively), with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ff5ca2c2b6ab8b5b38187b2bb4b1cd5
https://doi.org/10.1200/jco.2021.39.15_suppl.3075
https://doi.org/10.1200/jco.2021.39.15_suppl.3075
Autor:
Zhangguo Chen, Xuedong Liu, Xiaoguang Wang, Anthony D. Piscopio, Gan Zhang, Rachel A. Woolaver, Jing Wang, Brittany C. Waschke
Publikováno v:
Blood Cancer Discovery. 1:PO-54
PD1 blockade is effective in a subset of B-cell lymphoma patients (e.g., classical Hodgkin lymphomas); however, most patients do not respond to anti-PD1 therapy. To overcome PD1 resistance, we employ a newly developed isoform-selective histone-deacet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2329f1ee4caecaab9b29cf22ae27357
https://doi.org/10.1158/2643-3249.lymphoma20-po-54
https://doi.org/10.1158/2643-3249.lymphoma20-po-54
Autor:
Nicole A. LeFur, Kevin Koch, Anthony D. Piscopio, Paul J. Nichols, Tsung-Hsun Chuang, John Demattei, Bradley R. Barnett
Publikováno v:
Organic Letters. 8:1495-1498
[reaction: see text] The enantioselective conjugate addition of alpha-substituted malonates to aromatic nitroalkenes generates a stereocenter at the carbon bearing the aromatic group and an adjacent prochiral center from the alpha-substituted malonat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2764bee7991b5528254cf85cac6266e5
https://doi.org/10.1021/ol060398p
https://doi.org/10.1021/ol060398p